HPV Vaccination Should Be Part of Oncology Cost-Reduction Strategy

The impact of staggering increases in the cost of individual antineoplastic agents for patients and the overall healthcare system cannot be overstated, and there appears to be no realistic solution to the current dilemma that is acceptable to the parties involved in this ongoing debate.

Read full article (External website)

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply